Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II.
Shah
P K
PK
Atherosclerosis Research Center, Division of Cardiology and Burns and Allen research Institute, Department of Medicine, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, California, USA. shahp@cshs.org
Kaul
S
S
Nilsson
J
J
Cercek
B
B
D000818:Animals; D016632:Apolipoprotein A-I / Q000235:genetics / Q000502:physiology* / Q000627:therapeutic use; D001053:Apolipoproteins / Q000502:physiology; D001158:Arteries / Q000378:metabolism; D001161:Arteriosclerosis / Q000188:drug therapy / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D008075:Lipoproteins, HDL / Q000737:chemistry / Q000502:physiology* / Q000627:therapeutic use; D008081:Liposomes; D051379:Mice; D010743:Phospholipids / Q000008:administration & dosage
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D008075:Lipoproteins, HDL; D008081:Liposomes; D010743:Phospholipids